Opportunity Information: Apply for RFA CA 22 009
This funding opportunity, RFA-CA-22-009, is a National Institutes of Health (NIH) announcement from the National Cancer Institute (NCI) focused on supporting revision applications to existing NCI P50 Specialized Center grants. In plain terms, it is not a stand-alone, brand-new center grant competition. It is designed for organizations that already hold an active NCI P50 award and want to request additional support to modify and strengthen the ongoing, parent P50 by adding a new technological capability.
The central goal is to speed up cancer research progress within an already funded P50 center by incorporating a novel technology that was developed with NCI support through the Innovative Molecular Analysis Technologies (IMAT) program. Applicants are expected to propose a concrete expansion of one or more existing research questions in the parent award, or a clear plan to accelerate the parent project(s), specifically by integrating a new technical approach, platform, or instrument that originated from IMAT-backed development. A major emphasis is placed on independent validation and real-world readiness: the intent is to help promising, emerging IMAT technologies prove their performance and usefulness in appropriate research settings and communities, rather than remaining only at the prototype or early demonstration stage.
Programmatically, the FOA sits within the broader IMAT mission, which is to promote interdisciplinary collaboration and the development of innovative tools and methods that enable cancer research and accelerate scientific discovery. That means proposals are generally expected to bring together expertise across domains (for example, cancer biology or clinical oncology paired with engineering, computational methods, molecular analysis, or advanced instrumentation) and show how the technology addition will produce measurable gains in capability, throughput, accuracy, or interpretability for cancer research conducted under the parent P50. The opportunity is listed as "Clinical Trial Optional," which signals that applicants may propose work that includes a clinical trial component if appropriate, but a clinical trial is not required for eligibility under the announcement.
The award mechanism is a grant under a discretionary funding opportunity, and it is tied to the health and education activity category with CFDA number 93.394. The posted award ceiling is $150,000, indicating this is intended as a targeted, additive investment to integrate and validate a novel tool within an existing center structure, rather than to fund a large expansion comparable to a full center award. The original closing date shown for the opportunity was September 22, 2022, and the record creation date was January 3, 2022.
Eligibility is broad in the sense that many organization types can apply under NIH rules, including state and local governments, public and private institutions of higher education, independent school districts, special district governments, federally recognized tribal governments and other tribal entities, public housing authorities/Indian housing authorities, nonprofits with and without 501(c)(3) status, for-profit organizations (other than small businesses), and small businesses. The announcement also explicitly highlights additional categories of eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, non-U.S. entities (foreign organizations), and U.S. territories or possessions. Despite that breadth, the practical gatekeeping requirement is that the application must be a revision to a currently funded NCI P50 specialized center, since the purpose is to enhance and accelerate the active parent award through IMAT-origin technology integration.
Overall, this FOA is best understood as a catalytic supplement-like revision pathway for existing NCI P50 centers that want to incorporate a cutting-edge, NCI-supported IMAT technology into ongoing cancer research projects, generate independent validation data, and move the technology closer to broad usability by the relevant cancer research community.Apply for RFA CA 22 009
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2022-01-03.
- Applicants must submit their applications by 2022-09-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH/NCI RFA-CA-22-009 (Revision to Existing NCI P50 Centers to Add IMAT Technology)
1) What is RFA-CA-22-009?
RFA-CA-22-009 is a National Institutes of Health (NIH) funding announcement from the National Cancer Institute (NCI). It supports revision applications to existing, active NCI P50 Specialized Center grants to add a new technological capability that originated from NCI's Innovative Molecular Analysis Technologies (IMAT) program.
2) Is this a stand-alone, new P50 center competition?
No. This opportunity is not a brand-new center grant competition. It is specifically for organizations that already hold an active NCI P50 and want to submit a revision to strengthen the ongoing parent award by integrating an IMAT-developed technology.
3) What is the main purpose of this funding opportunity?
The main purpose is to accelerate cancer research progress within an already funded P50 center by incorporating a novel IMAT-origin technology. The intent is to help a promising technology move beyond an early demonstration stage by generating stronger evidence of performance and usefulness in appropriate research settings.
4) What kind of technology is expected to be added?
The proposed technology addition is expected to be a new technical approach, platform, or instrument that was developed with NCI support through the IMAT program. The revision should clearly describe how this capability will be integrated into the ongoing P50 research.
5) What should the revision application propose to do?
Applicants are expected to propose a concrete expansion of one or more existing research questions in the parent P50 award, or a clear plan to accelerate parent project(s), specifically through integration of the IMAT-origin technology. The revision should show how the new capability strengthens what the center is already doing.
6) What does "independent validation" mean in the context of this opportunity?
A major emphasis of this opportunity is on independent validation and real-world readiness. The intent is to help emerging IMAT technologies demonstrate performance and usefulness in appropriate research settings and communities, rather than remaining only as prototypes or early proof-of-concept demonstrations.
7) How does this FOA relate to the IMAT program?
This funding opportunity sits within the broader mission of IMAT, which supports interdisciplinary collaboration and the development of innovative tools and methods that enable cancer research and accelerate scientific discovery. The revision is meant to bring an IMAT-supported technology into an existing NCI P50 center to enhance research capabilities.
8) What kinds of teams or expertise are expected?
Proposals are generally expected to reflect interdisciplinary collaboration. Examples described include combining cancer biology or clinical oncology expertise with engineering, computational methods, molecular analysis, or advanced instrumentation in order to produce measurable gains for the parent P50's cancer research.
9) What types of improvements should the technology integration deliver?
The revision should show how adding the technology will produce measurable gains in capability for cancer research conducted under the parent P50, such as improvements in capability, throughput, accuracy, or interpretability.
10) Are clinical trials required?
No. The opportunity is listed as Clinical Trial Optional. That means a clinical trial component may be proposed if appropriate, but a clinical trial is not required for eligibility under this announcement.
11) What is the maximum award amount (ceiling) listed?
The posted award ceiling is $150,000. This indicates a targeted, additive investment intended to integrate and validate a novel tool within an existing center structure, rather than supporting a large expansion comparable to a full center award.
12) Is this funding described as a supplement?
The announcement is described as supporting revision applications to an active NCI P50. Based on the description provided, it functions like a catalytic, supplement-like revision pathway to incorporate and validate IMAT-origin technology within the existing center.
13) What is the activity category and CFDA number associated with this opportunity?
The opportunity is tied to the health and education activity category with CFDA number 93.394.
14) Who is eligible to apply?
Eligibility under NIH rules is described broadly and includes many organization types (for example, various levels of government, higher education institutions, nonprofits, for-profits other than small businesses, and small businesses). The announcement also highlights numerous specific categories such as minority-serving institutions, tribal entities, faith-based or community-based organizations, eligible federal agencies, foreign organizations, and U.S. territories or possessions.
15) What is the key practical eligibility requirement despite the broad list?
Despite the wide range of eligible applicant organization types, the key gatekeeping requirement is that the application must be a revision to a currently funded NCI P50 Specialized Center grant. The purpose is to enhance and accelerate the active parent award through integration of IMAT-origin technology.
16) Can non-U.S. entities apply?
Yes. The announcement explicitly includes non-U.S. entities (foreign organizations) among the highlighted eligible applicant categories. However, the application still must be a revision to an active NCI P50, which is the central practical requirement described.
17) What is the original closing date and record creation date listed?
The original closing date shown is September 22, 2022, and the record creation date is January 3, 2022.
18) What is NCI trying to accomplish by offering this specific revision pathway?
NCI is aiming to speed progress within ongoing NCI P50 centers by enabling them to incorporate cutting-edge, NCI-supported IMAT technologies, generate validation evidence in real research environments, and help move those technologies closer to broad usability by the relevant cancer research community.
Browse more opportunities from the same category: Education, Health
Next opportunity: Cooperative Endangered Species Conservation Fund: Recovery Land Acquisition Grant Program
Previous opportunity: The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 22 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 22 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional) Apply for RFA CA 22 011 Funding Number: RFA CA 22 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) Apply for PAR 22 057 Funding Number: PAR 22 057 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) Apply for RFA DA 22 037 Funding Number: RFA DA 22 037 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional) Apply for PAR 22 092 Funding Number: PAR 22 092 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) Apply for RFA DA 22 038 Funding Number: RFA DA 22 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) Apply for PAR 22 091 Funding Number: PAR 22 091 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) Apply for PAR 22 090 Funding Number: PAR 22 090 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) Apply for PAR 22 084 Funding Number: PAR 22 084 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) Apply for RFA TR 22 011 Funding Number: RFA TR 22 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Stimulating Access to Research in Residency (StARR) (R38) Apply for RFA HL 23 006 Funding Number: RFA HL 23 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) Apply for PAR 22 083 Funding Number: PAR 22 083 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) Apply for PAR 22 099 Funding Number: PAR 22 099 Agency: National Institutes of Health Category: Education, Health Funding Amount: $40,000 |
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) Apply for PAR 22 058 Funding Number: PAR 22 058 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Evaluating the Impact of COVID-19 Pandemic-related Food and Housing Policies and Programs on Health Outcomes in Health Disparity Populations (R01 Clinical Trial Optional) Apply for RFA NR 22 001 Funding Number: RFA NR 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional) Apply for RFA MH 22 130 Funding Number: RFA MH 22 130 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed) Apply for RFA NS 22 035 Funding Number: RFA NS 22 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 014 Funding Number: RFA CA 22 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) Apply for RFA DA 23 003 Funding Number: RFA DA 23 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) Apply for PAR 22 086 Funding Number: PAR 22 086 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) Apply for PAR 22 085 Funding Number: PAR 22 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 22 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.